Bispecific Antibodies
New Frontier of Bispecific Antibody BD in China After PD-(L)1/VEGF
China’s BsAb deals hit $9.26B in H1 2025. Innovent, Hengrui, and SystImmune shift beyond PD-(L)1/VEGF to Ang2/VEGF, T-cell engagers, and novel dual-pathway drugs.